Kestra Medical Technologies (NASDAQ: KMTS) insider transactions
In the twelve months to 10 November 2026, executives and directors of Kestra Medical Technologies reported 54 open-market sales of 605,120 shares ($15.5m) and 1 open-market purchase of 10,000 shares ($199,800), by 11 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 3 November 2026 | Moran Timothy P. | Chief Business Officer | Open-market sale | −3,192 | $29.56 | 63,153 | Form 4 |
| 29 October 2026 | Mahboob Vaseem | Chief Financial Officer | Option exercise, 10b5-1 plan | +4,788 | $17.00 | 65,397 | Form 4 |
| 29 October 2026 | Mahboob Vaseem | Chief Financial Officer | Open-market sale, 10b5-1 plan | −4,788 | $30.60 | 60,609 | Form 4 |
| 28 October 2026 | Mahboob Vaseem | Chief Financial Officer | Option exercise, 10b5-1 plan | +39,903 | $17.00 | 100,512 | Form 4 |
| 28 October 2026 | Mahboob Vaseem | Chief Financial Officer | Open-market sale, 10b5-1 plan | −39,903 | $30.48 | 60,609 | Form 4 |
| 27 October 2026 | Umberger Traci S | See Remarks | Option exercise, 10b5-1 plan | +30,000 | $17.00 | 225,825 | Form 4 |
| 27 October 2026 | Umberger Traci S | See Remarks | Open-market sale, 10b5-1 plan | −30,000 | $30.03 | 195,825 | Form 4 |
| 27 October 2026 | Mahboob Vaseem | Chief Financial Officer | Option exercise, 10b5-1 plan | +34,809 | $17.00 | 95,418 | Form 4 |
| 27 October 2026 | Mahboob Vaseem | Chief Financial Officer | Open-market sale, 10b5-1 plan | −34,809 | $30.04 | 60,609 | Form 4 |
| 21 October 2026 | Umberger Traci S | See Remarks | Option exercise, 10b5-1 plan | +100,000 | $17.00 | 295,825 | Form 4 |
| 21 October 2026 | Umberger Traci S | See Remarks | Open-market sale, 10b5-1 plan | −96,404 | $27.15 | 199,421 | Form 4 |
| 21 October 2026 | Umberger Traci S | See Remarks | Open-market sale, 10b5-1 plan | −3,596 | $28.09 | 195,825 | Form 4 |
| 20 October 2026 | Webster Brian Daniel | See Remarks | Open-market sale, 10b5-1 plan | −13,316 | $29.52 | 446,899 | Form 4 |
| 20 October 2026 | Webster Brian Daniel | See Remarks | Open-market sale, 10b5-1 plan | −1,684 | $29.89 | 445,215 | Form 4 |
| 30 September 2026 | Cohen Raymond W | Director | Open-market sale | −3,330 | $29.28 | 54,790 | Form 4 |
| 21 September 2026 | Kwo Elizabeth | Director | Open-market sale | −4,010 | $24.26 | 14,116 | Form 4 |
| 9 September 2026 | Schwartz Jeffrey Lawrence | Director | Grant or award | +7,217 | — | 14,236 | Form 4 |
| 9 September 2026 | Ladone Mary Kay | Director | Grant or award | +7,217 | — | 44,724 | Form 4 |
| 9 September 2026 | Reilly Kevin C | Director | Grant or award | +7,217 | — | 12,585 | Form 4 |
| 9 September 2026 | Hanley Conor | Director | Grant or award | +7,217 | — | 13,489 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Kestra Medical Technologies page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.